Bionano Genomics, Inc. (NASDAQ:BNGO) has a beta value of 0 and has seen 7,301,863 shares traded in the recent trading session. The company, currently valued at $112.98 Million, closed the recent trade at $0.82 per share which meant it lost -$0.04 on the day or -5.01% during that session. The BNGO stock price is -473.17% off its 52-week high price of $4.7 and 69.51% above the 52-week low of $0.25. If we look at the company’s 10-day average daily trading volume, we find that it stood at 25.28 Million shares traded. The 3-month trading volume is 23.91 Million shares.
The consensus among analysts is that Bionano Genomics, Inc. (BNGO) is a Buy stock at the moment, with a recommendation rating of 1.7. None of the analysts rate the stock as a Sell, while none rate it as Overweight. None out of 3 have rated it as a Hold, with 3 advising it as a Buy. None have rated the stock as Underweight. The expected earnings per share for the stock is -$0.09.
Bionano Genomics, Inc. (NASDAQ:BNGO) trade information
Despite being -5.01% in the red today, the stock has traded in the green over the last five days, with the highest price hit on Friday, Aug 07 when the BNGO stock price touched $1.01 or saw a rise of 17.72%. Year-to-date, Bionano Genomics, Inc. shares have moved -32.98%, while the 5-day performance has seen it change 4.92%. Over the past 30 days, the shares of Bionano Genomics, Inc. (NASDAQ:BNGO) have changed 56.79%. Short interest in the company has seen 5.07 Million shares shorted with days to cover at 0.21.
Wall Street analysts have a consensus price target for the stock at $1.47, which means that the shares’ value could jump 79.27% from current levels. The projected low price target is $0.9 while the price target rests at a high of $2. In that case, then, we find that the current price level is +143.9% off the targeted high while a plunge would see the stock lose 9.76% from current levels.
Bionano Genomics, Inc. (BNGO) estimates and forecasts
Figures show that Bionano Genomics, Inc. shares have underperformed across the wider relevant industry. The company’s shares have lost -15.31% over the past 6 months, with this year growth rate of -75.79%, compared to 12% for the industry. Other than that, the company has, however, increased its growth outlook for the 2020 fiscal year revenue. Growth estimates for the current quarter are 87.3% and 86.4% for the next quarter. Revenue growth from the last financial year stood is estimated to be -32%.
3 analysts offering their estimates for the company have set an average revenue estimate of $860Million for the current quarter. 3 have an estimated revenue figure of $1.85 Million for the next quarter concluding in September 01, 2020. Year-ago sales stood $2.17 Million and $3.31 Million respectively for this quarter and the next, and analysts expect sales will grow by -60.5% for the current quarter and -44.2% for the next.
Earnings growth for 2020 is a modest -8.2%.
Bionano Genomics, Inc. (NASDAQ:BNGO)’s Major holders
Insiders own 10.41% of the company shares, while shares held by institutions stand at 11.26% with a share float percentage of 12.56%. Investors are also buoyed by the number of investors in a company, with Bionano Genomics, Inc. having a total of 21 institutions that hold shares in the company. The top two institutional holders are Bank Julius Baer & Co. Ltd, Zurich with over 452.92 Thousand shares worth more than $206.08 Thousand. As of March 30, 2020, Bank Julius Baer & Co. Ltd, Zurich held 0.33% of shares outstanding.
The other major institutional holder is Geode Capital Management, LLC, with the holding of over 246.97 Thousand shares as of March 30, 2020. The firm’s total holdings are worth over $112.37 Thousand and represent 0.18% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are Fidelity NASDAQ Composite Index Tracking Stock and Vanguard Extended Market Index Fund. As of May 30, 2020, the former fund manager holds about 0.15% shares in the company for having 209443 shares of worth $94.04 Thousand while later fund manager owns 177.51 Thousand shares of worth $80.77 Thousand as of March 30, 2020, which makes it owner of about 0.13% of company’s outstanding stock.